Somai has partnered with Kiseki Plant Factory (Thailand) to support the global distribution of Kiseki's medicinal cannabis flower across Somai's international medical markets.
Through this collaboration, Kiseki's medicinal cannabis products will become available for the first time in the UK, leveraging Somai's established regulatory infrastructure and pharmaceutical distribution network. This milestone represents one of the first introductions of a Japanese-origin cannabis brand into Western prescription markets. The partnership will continue to expand in phases, aligned with applicable market authorization processes and regulatory requirements.
Kiseki's flower is cultivated in a state-of-the-art indoor facility operating under the Control Union Medical Cannabis Standard – GAP, applying Japanese-inspired agricultural engineering and quality control protocols designed for medical use.
"Japanese quality is the result of precise plant-factory engineering, disciplined cultivation processes, and carefully selected genetics," said Kohei Yamada, Founder and CEO of Kiseki Plant Factory (Thailand). "We are proud to collaborate with Somai to bring our medicinal cannabis to patients worldwide through a partner that understands regulated medical markets."
"This collaboration reflects Somai's role in working to distribute various craft indoor brands through its global distribution platform," said Michael Sassano, Founder and Interim CEO of Somai. "Somai's ability to navigate EU-GMP regulatory frameworks to commercialization of unique international brands demonstrates careful thought to reach many demographics in the medical community through diversified cultural offerings that meet the high expectations of regulators, prescribers, and patients worldwide."
For more information:
Somai Pharmaceuticals
www.somaipharma.eu
